← Search & browse all drugs
CARDIOVASCULAR SYSTEM › DIURETICS › DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION › High-ceiling diuretics and potassium-sparing agents
bumetanide and potassium-sparing agents
C03EB02
Forms & Strengths
- Tablets: 0.5mg, 1mg, 2mg
- Injection: 0.25mg/mL
- Combination with potassium-sparing agents
Adult Dosing
- Edema: 0.5-2mg orally once daily
- Hypertension: 0.5-1mg orally twice daily
- IV: 0.5-1mg over 1-2 minutes, may repeat
Pediatric Dosing
- Not established for children under 18 years
- Use with caution, dosing based on clinical judgment
Indications
- Edema associated with congestive heart failure
- Edema associated with hepatic cirrhosis
- Nephrotic syndrome
- Hypertension
Mechanism of Action
- Inhibits sodium and chloride reabsorption in the ascending loop of Henle
- Increases renal excretion of sodium, chloride, and water
- Potassium-sparing agents reduce potassium loss
Contraindications
- Anuria
- Hepatic coma
- Severe electrolyte depletion
- Hypersensitivity to bumetanide or sulfonamides
Adverse Reactions
- Hypokalemia
- Dehydration
- Orthostatic hypotension
- Azotemia
- Hyperuricemia
- Gout
Drug Interactions
- Potentiates effects of other antihypertensives
- Increases risk of ototoxicity with aminoglycosides
- Increases risk of nephrotoxicity with cephalosporins
- NSAIDs may reduce diuretic and antihypertensive effects
Curated Content: Needs Vetting Before Put to Clinical Use